UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Shaping Up To Be Strong Growth Story

UBS maintains a 'Buy' on Par Pharmaceutical (NYSE: PRX) price target raised from $39 to $42.

UBS analyst says, "Our takeaway: Better-than-expected EPS growth guidance; Raising numbers - Management gave an impressive 15% 2012-2014 cash EPS growth guidance vs. 7% cons. Par’s more robust pipeline and R&D throughput post the Anchen/Edict acquisitions and continued business development should position it will for medium-long term growth. We pushed out Exforge’s launch from 2012 to 2014 which reduced our 2012E EPS by $0.03. For 2013 and 2014 we added FTFs (e.g. Mirapex ER, Coreg CR, and Luvox CR) and several other non-FTF ANDA’s to the model which raised our 2013E and 2014E EPS by $0.14 and $0.95, respectively."

For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.

Shares of Par Pharmaceutical closed at $34.01 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Downgrades Planisware SA (PLNW:FP) to Neutral
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• Berenberg Upgrades Sixt SE (SIX2:GR) to Buy